CN108815484A - A kind of pharmaceutical composition and purposes for treating Parkinson's disease - Google Patents

Abstract

The invention discloses a pharmaceutical composition for treating Parkinson's disease and its use. The composition is made of the following raw materials in parts by weight: 40-60 parts of Eucommia, 0.3-0.7 parts of Dendrobium, 0.5-1 part of Rehmannia, Dried ginger 0.5‑1 part. It has been proved by experiments that the pharmaceutical composition for the treatment of Parkinson's disease of the present invention can significantly improve the limb movement coordination ability of PD model mice and increase the concentration of dopamine and its metabolites in the striatum of the brain to the Parkinson's disease model caused by MPTP in mice. The content of hydroxyphenylacetic acid and high vanillic acid has a clear therapeutic effect on Parkinson's disease.

Description

A kind of pharmaceutical composition and application for treating Parkinson's disease

technical field

The invention belongs to the field of traditional Chinese medicine, and relates to a pharmaceutical composition for treating Parkinson's disease and its application.

Background technique

Parkinson's disease (PD) is a common neurodegenerative disease in middle-aged and elderly people. Clinically, it is characterized by resting tremor, bradykinesia, muscle rigidity, and posture and gait disturbance, which seriously affect the patient's movement and living ability, and can lead to disability. At present, the treatment of Parkinson's disease is still based on drug therapy. Western medicine commonly used drugs for the treatment of the disease are anticholinergic drugs, dopamine replacement therapy and dopamine receptor agonists. Although the symptoms can be alleviated, the disease cannot be controlled. Coupled with the long-term dependence of chronic diseases on drugs, the condition will aggravate over time, making various physiological functions worse or even exhausted.

In recent years, with the vigorous development of traditional Chinese medicine in my country, more and more scholars have extended the research and exploration of PD treatment to the field of traditional Chinese medicine, and screened out some traditional Chinese medicine compositions that are effective for the treatment of PD from many traditional Chinese medicine compounds, but In the past, the use of traditional Chinese medicine was mainly based on experience summarization, lacking strict scientific proof basis, unable to be widely used in clinical treatment, and it is difficult to promote research on the mechanism of action of traditional Chinese medicine compositions.

Parkinson's disease belongs to the category of "tremor syndrome" in traditional Chinese medicine. Traditional Chinese medicine believes that its pathogenesis lies in the deficiency of liver and kidney, and nourishing the liver and kidney is an important rule for preventing and treating Parkinson's disease. Eucommia ulmoides is a commonly used medicine for invigorating the liver and kidney, strengthening bones and muscles. "The five zang organs are bitter and want to nourish and relieve" says, the kidneys are bitter and dry, eat pungent to moisten it quickly, and eat sweet to relieve the liver's bitterness. Eucommia ulmoides is full of pungent sweetness, which can relieve the suffering of the liver and kidney and make up for its deficiency. Tonify the kidney and nourish the liver, then the essence and blood will be self-sufficient, and the shaking will stop by itself.

This drug combination uses Eucommia ulmoides as the monarch drug, which is pungent and sweet in nature, good at entering the liver and kidney, warming and nourishing yang, nourishing the liver and kidney, and strengthening the bones and muscles, so it can make the kidneys full and bones strong, the liver full and muscles strong, muscles and bones intertwined, flexion and stretching Profit, clever tricks. Guyang does not grow, so I use Dendrobium and Rehmannia glutinosa to benefit Yin. Dendrobium dendrobium is sweet, flat and moist, nourishes essence and strengthens yin, and can also "eliminate numbness...replenish five viscera and fatigue". It can benefit the blood and qi, "remove blood stagnation, fill bone marrow, and grow muscles". The two flavors not only nourish yin and blood, have the meaning of seeking yang in yin, but also make yang medicine dry and strong. Therefore, Eucommia can obtain dendrobium and rehmannia glutinosa, which are warm but not dry, and yin and yang are obtained together. Dried ginger is pungent and hot, and Shi Zhen said that "it can lead blood medicine into the blood, and qi medicine into the qi, and it can also remove evil and nourish the new, with the meaning of yang and yin growth", so it can benefit the limbs, Open up the meridians and promote various medicines. When the four medicines are used together, the yang gradually grows and the yin grows, and the positive gradually recovers while the deficiency and evil disappear. Eucommia ulmoides, Dendrobium, and Rehmannia glutinosa are all top grades in the "Book of Materia Medica", and they can be used for a long time to lighten the body and endure aging, while dried ginger is a product that can be used for both medicine and food, which is good for long-term consumption by chronically ill people.

Contents of the invention

The purpose of the present invention is to overcome the deficiencies of the prior art and provide a pharmaceutical composition for treating Parkinson's disease.

The second object of the present invention is to provide a use of the pharmaceutical composition for treating Parkinson's disease in preparing a drug for treating Parkinson's disease.

Technical scheme of the present invention is summarized as follows:

A pharmaceutical composition for treating Parkinson's disease, which is prepared from the following raw materials in parts by weight: 40-60 parts of Eucommia ulmoides, 0.3-0.7 parts of dendrobium, 0.5-1 part of raw rehmannia, and 0.5-1 part of dried ginger.

Preferably: 50 parts of Eucommia ulmoides, 0.5g part of Dendrobium, 0.75g part of raw root, 0.75g part of dried ginger.

Use of the aforementioned pharmaceutical composition for treating Parkinson's disease in the preparation of a drug for treating Parkinson's disease.

It has been proved by experiments that the pharmaceutical composition for the treatment of Parkinson's disease of the present invention is effective on mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine, MPTP) induced Parkinson's disease model, can significantly improve the limb motor coordination ability of PD model mice, increase the content of dopamine and its metabolites dihydroxyphenylacetic acid and homovanillic acid in the brain striatum , has a clear therapeutic effect on Parkinson's disease.

Detailed ways

The present invention will be further described below in conjunction with specific examples.

Example 1

A medicinal composition for treating Parkinson's disease, which is prepared from the following raw materials: 50 g of Eucommia ulmoides, 0.5 g of dendrobium, 0.75 g of rehmannia root, and 0.75 g of dried ginger.

The specific preparation method is:

According to the ratio of adding 10 mL of 75% ethanol aqueous solution to 1 g of the above raw materials, heat and reflux, filter, extract twice, each time for 2 h, and concentrate the combined extracts to 1 g/mL.

Example 2

A pharmaceutical composition for treating Parkinson's disease, which is prepared from the following raw materials: Eucommia ulmoides 40g, dendrobium 0.3g, rehmannia root 0.5g, and dried ginger 0.5g.

The preparation method is the same as in Example 1.

Example 3

A pharmaceutical composition for treating Parkinson's disease, which is prepared from the following raw materials: 60g of Eucommia ulmoides, 0.7g of dendrobium, 1g of raw rehmannia, and 1g of dried ginger.

The preparation method is the same as in Example 1.

Example 4

A pharmaceutical composition for treating Parkinson's disease, which is prepared from the following raw materials: Eucommia ulmoides 40g, dendrobium 0.7g, raw rehmannia 1g, and dried ginger 1g.

The preparation method is the same as in Example 1.

Example 5

A pharmaceutical composition for treating Parkinson's disease, which is prepared from the following raw materials: 60g of Eucommia ulmoides, 0.3g of dendrobium, 0.5g of rehmannia root, and 0.5g of dried ginger.

The preparation method is the same as in Example 1.

experiment

Therapeutic effect of a pharmaceutical composition for treating Parkinson's disease on Parkinson's disease

The method of intraperitoneal injection of MPTP (1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine) was used to replicate the mouse Parkinson's disease model:

Select C57BL/6 mouse, be divided into 7 groups at random, namely normal control group, PD model group, embodiment 1 group, embodiment 2 group, embodiment 3 group, embodiment 4 group, embodiment 5 group, each group 10 Among them, except the normal control group, PD modeling was required for the other groups. Each animal in the normal control group and the PD model group was intragastrically given 0.1ml/10g of normal saline at a fixed time every day, and the Example 1 group, the Example 2 group, the Example 3 group, the Example 4 group, and the Example 5 group were given intragastric administration every day. The corresponding drugs were given at 0.1ml/10g for 3 days by intragastric administration. From the 4th day, the normal control group was intraperitoneally injected with normal saline 0.1ml/10g after intragastric administration for 1 hour, and the PD model group and each example group were intraperitoneally injected with MPTP at a final concentration of 30mg/kg according to 0.1ml/10g after intragastric administration for 1 hour. Continuous gavage and intraperitoneal injection for 5 days. On the 8th day of intragastric administration, 1 hour after intraperitoneal injection, the effect of the drug on the coordination function of the limbs of the experimental animals was detected by climbing rod test, rotating rod test and hanging test; Effects of drugs on the contents of dopamine (DA) and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the striatum of experimental mice.

Rod climbing experiment: A metal rod with a length of 60 cm and a diameter of 1 cm was selected for the experiment, and gauze was wrapped around the outside to prevent slipping, and the bottom was fixed on an iron stand. Put the tested mouse head down on the top of the metal pole, record the time for the mouse to climb from the top of the pole to the bottom of the pole, and start timing when the mouse's hind legs leave the top and stop when it completely touches the base. The mice in each group were trained to climb poles on the 5th-7th day of gavage, so that they were familiar with and adapted to climbing poles. On the 8th day, that is, 1 hour after the last injection of MPTP, it was the formal experiment. The climbing time of each mouse was recorded 3 times, and the average value was used for statistical analysis. If the mouse stopped midway or climbed backward, it was measured again.

Rotarod test: place the mouse on the rotarod apparatus, adjust the rotation speed to 20r/min, record the time elapsed from the time the mouse turns on the rotarod until it falls off the rotarod, and the measurement time is 5 minutes. The mice in each group were trained on the rotarod behavior on the 5th-7th day of gavage, so that they were familiar with and adapted to the rotarod activity. On the 8th day, that is, 1 hour after the last injection of MPTP, it was the formal experiment. Each mouse was measured 5 times, and the average value was taken. The detection interval of the same mouse was 30 minutes.

Suspension test: hang both forelimbs of the tested mice on a horizontal wire. If the mouse grasps the wire with both hind limbs, it will score 3 points; if it grasps the wire with one hind limb, it will score 2 points; 1 point if the wire does not live. The mice in each group were subjected to the suspension test on the 8th day, that is, 1 hour after the last injection of MPTP, and the scores were calculated and analyzed statistically.

Table 1 mouse behavior comparison ( n=10)

Note: Compared with normal control group, ^## P<0.01; compared with PD model group, *P<0.05, **P<0.01

The secretion of neurotransmitters is an important performance to maintain normal nerve function, but the loss of neurons will inevitably affect the secretion of neurotransmitters. In order to further clarify the therapeutic effect of drugs on the MPTP-induced experimental mouse Parkinson's disease model, high-performance liquid chromatography-electrochemical detection (HPLC-ECD) was used to detect dopamine (DA) and The content of its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA).

Table 2 Comparison of striatal neurotransmitters in mice ( n=10)

Note: Compared with normal control group, ^## P<0.01; compared with PD model group, *P<0.05, **P<0.01.

Claims (3)

1. A pharmaceutical composition for the treatment of Parkinson's disease, characterized in that it is made of the following raw materials in parts by weight: 40-60 parts of Eucommia ulmoides, 0.3-0.7 part of dendrobium, 0.5-1 part of Rhizoma Rhizoma, 0.5-1 part of dried ginger share. 2. A kind of pharmaceutical composition for treating Parkinson's disease according to claim 1, characterized in that 50 parts of Eucommia ulmoides, 0.5 part of Dendrobium, 0.75 part of Radix Ginger, and 0.75 part of Dried Ginger. 3. The use of a pharmaceutical composition for treating Parkinson's disease according to claim 1 or 2 in the preparation of a drug for treating Parkinson's disease.